XNYS · Healthcare · Diagnostics & Research
Revvity is a global life sciences and diagnostics company formed in 2023 following the rebranding of PerkinElmer. The company operates in two segments: life sciences, which provides reagents and instruments for biopharma and academic research, and signals software, and diagnostics, which offers tools in immunodiagnostics and newborn and reproductive health. Revvity's products and services are sold worldwide, with major markets in the US, Europe, and China.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-05 | Q1 2026 | 1.02 | 1.06 | +3.92% | $711.1M | ✅ Beat | +1.49% | +7.58% | — |
| 2026-02-02 | Q4 2025 | 1.58 | 1.70 | +7.59% | $772.1M | ✅ Beat | +1.82% | -3.99% | -8.03% |
| 2025-10-27 |
| Q3 2025 |
| 1.14 |
| 1.18 |
| +3.51% |
| $698.9M |
| ✅ Beat |
| — |
| — |
| — |
| 2025-07-28 | Q2 2025 | 1.14 | 1.18 | +3.51% | $720.3M | ✅ Beat | — | — | — |
| 2025-04-28 | Q1 2025 | 0.95 | 1.01 | +6.32% | $664.8M | ✅ Beat | -0.42% | -2.35% | -3.91% |
| 2025-01-31 | Q4 2024 | 1.38 | 1.42 | +2.90% | $729.4M | ✅ Beat | -1.93% | -5.76% | -12.48% |
| 2024-11-04 | Q3 2024 | 1.13 | 1.28 | +13.27% | $684.0M | ✅ Beat | +0.91% | -3.35% | -6.96% |
| 2024-07-29 | Q2 2024 | 1.12 | 1.22 | +8.93% | $691.7M | ✅ Beat | +1.25% | -4.30% | -3.42% |
Showing last 8 quarters.